Abstract: In alternative embodiments, provided are methods for treating and ameliorating a cancer, or recurrence of a cancer such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 (or rebecsinib) and second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as dasatinib. In alternative embodiments, provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 and second drug. In alternative embodiments, provided are methods for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 and second drug.

Abstract: The disclosure provides a theseometer or proprioceptometer for objectively quantifying the proprioceptive performance of a subject such as a human. The disclosed theseometer is a device comprising a clear, rigid material or screen having or exhibiting a distinguishable target embraced by a series of concentric rings, a digital camera with a lens concentric to the target, a base unit comprising an electronic processor and memory for analyzing data and, optionally, a wheeled base to provide mobility and portability.

Abstract: The disclosure provides a theseometer or proprioceptometer for objectively quantifying the proprioceptive performance of a subject such as a human. The disclosed theseometer is a device comprising a clear, rigid material or screen having or exhibiting a distinguishable target embraced by a series of concentric rings, a digital camera with a lens concentric to the target, a base unit comprising an electronic processor and memory for analyzing data and, optionally, a wheeled base to provide mobility and portability.